EsoCap Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Debt

  • Latest Deal Amount
  • $614K

  • Investors
  • 3

EsoCap General Information

Description

Operator of a drug delivery platform designed for the treatment of diseases of the upper gastrointestinal tract. The company's technology offers targeted and long-lasting treatment of patients' esophageal mucosa using a capsule containing a thin film loaded with a drug, enabling patients with esophageal diseases to improve their lives.

Contact Information

Website
www.esocapbiotech.ch
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Malzgasse 9
  • 4052 Basel
  • Switzerland
+41 061
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
LOHAS & Wellness, Life Sciences
Corporate Office
  • Malzgasse 9
  • 4052 Basel
  • Switzerland
+41 061

EsoCap Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EsoCap Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Debt - General 01-Jul-2025 $614K Completed
6. Later Stage VC 05-Jul-2024 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 18-Dec-2023 Completed Clinical Trials - Phase 2
4. Early Stage VC 18-Nov-2021 Completed Clinical Trials - Phase 2
3. Early Stage VC 01-Dec-2020 Completed Clinical Trials - Phase 2
2. Early Stage VC 30-Jul-2019 $3.61M Completed Startup
1. Early Stage VC 13-Jul-2018 $3.61M $3.61M Completed Startup
To view EsoCap’s complete valuation and funding history, request access »

EsoCap Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary Shares
Ordinary Shares
Ordinary Shares
Ordinary Shares 395,887 $0.111738 $16.76 $16.76 1x $16.76 17.56%
Ordinary Shares 199,480 $0.111738 $20.11 $20.11 1x $20.11 8.85%
To view EsoCap’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

EsoCap Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a drug delivery platform designed for the treatment of diseases of the upper gastrointestinal tract. The com
Drug Discovery
Basel, Switzerland
5 As of 2026

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EsoCap Competitors (1)

One of EsoCap’s competitors is RAPT Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
RAPT Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 1 of 1 competitors. Get the full list »

EsoCap Patents

  • 76

    Total Documents Applications and Grants

  • Total Patents Families

  • 46

    Granted

  • 24

    Pending

  • Expiring in next 12 mo

EsoCap Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026104312-A1 Stable mometasone furoate compositions Pending 14-Nov-2024
DE-102024133414-A1 Stable mometasone furoate-containing formulations Pending 14-Nov-2024
AU-2023284843-A1 Drug delivery system comprising a reflux inhibitor for the application to esophageal mucous membranes Pending 07-Jun-2022
EP-4536194-A1 Drug delivery system comprising a reflux inhibitor for the application to esophageal mucous membranes Pending 07-Jun-2022
US-20250228772-A1 Drug delivery system comprising a reflux inhibitor for the application to esophageal mucous membranes Pending 07-Jun-2022 A61K9/006
To view EsoCap’s complete patent history, request access »

EsoCap Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EsoCap Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
SandStorm VC Venture Capital Minority
Canton of Basel-Stadt Government Minority
Carela Holding Family Office Minority
To view EsoCap’s complete investors history, request access »

Ready to get started?

Request a free trial

EsoCap FAQs

  • When was EsoCap founded?

    EsoCap was founded in 2017.

  • Where is EsoCap headquartered?

    EsoCap is headquartered in Basel, Switzerland.

  • What is the size of EsoCap?

    EsoCap has 5 total employees.

  • What industry is EsoCap in?

    EsoCap’s primary industry is Drug Discovery.

  • Is EsoCap a private or public company?

    EsoCap is a Private company.

  • What is EsoCap’s current revenue?

    The current revenue for EsoCap is .

  • How much funding has EsoCap raised over time?

    EsoCap has raised $18.1M.

  • Who are EsoCap’s investors?

    SandStorm VC, Canton of Basel-Stadt, and Carela Holding have invested in EsoCap.

  • Who are EsoCap’s competitors?

    RAPT Therapeutics is a competitor of EsoCap.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process